{
    "clinical_study": {
        "@rank": "70519", 
        "acronym": "VARIABLE", 
        "arm_group": [
            {
                "arm_group_label": "Group A: Vildagliptin plus metformin", 
                "arm_group_type": "Experimental", 
                "description": "Will receive Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily)"
            }, 
            {
                "arm_group_label": "Group B: Glimepiride plus metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "Will receive Glimepiride 1-6 mg once daily as an add-on to metformin (1000-1500mg daily)"
            }
        ], 
        "brief_summary": {
            "textblock": "Compare the effect of Vildagliptin plus Metformin versus Glimepiride plus Metformin on\n      glucose variability in T2DM patients."
        }, 
        "brief_title": "Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients who have given written informed consent to participate in the study.\n\n          2. Type 2 Diabetes Mellitus patients either Male or female from 18 - 75 years of age\n             (both inclusive).\n\n          3. Patients who are uncontrolled on metformin monotherapy for at least past 4 weeks\n             (1000-1500 mg daily and HbA1c > 7.5 - 9%).\n\n          4. Patients with HbA1C levels within the range > 7.5% - 9%. (If a past value is\n             available within the last 12 weeks, it would be considered acceptable provided it was\n             obtained after at least 4 weeks of metformin therapy 1000-1500 mg daily).\n\n        Exclusion Criteria:\n\n          1. Age > 75 years ; BMI <22 or >40 kg/m2\n\n          2. Patients who are on Insulin therapy at the time of study entry.\n\n          3. Type 1 Diabetes Mellitus patients.\n\n          4. Patients with severe renal (creatinine clearance < 50 ml/min) or hepatic impairment\n             (including pre-treatment ALT or AST > 3 x ULN).\n\n             Creatinine clearance will be estimated from serum creatinine using Cockcroft-Gault\n             formula (Cockcroft and Gault, 1976)\n\n          5. Patients with contraindications as mentioned in the Summary of Product\n             Characteristics (SPCs) for vildagliptin, metformin, glimepiride, vildagliptin plus\n             metformin and glimiperide plus metformin.\n\n        Other protocol defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "324", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01910441", 
            "org_study_id": "CLAF237AIN03"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A: Vildagliptin plus metformin", 
                "description": "Vildagliptin 50 mg twice daily", 
                "intervention_name": "Vildagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Group A"
            }, 
            {
                "arm_group_label": "Group B: Glimepiride plus metformin", 
                "description": "Glimepiride 1-6 mg once daily", 
                "intervention_name": "Glimepiride", 
                "intervention_type": "Drug", 
                "other_name": "Group B"
            }, 
            {
                "arm_group_label": [
                    "Group A: Vildagliptin plus metformin", 
                    "Group B: Glimepiride plus metformin"
                ], 
                "description": "Metformin (1000-1500 mg daily)", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Vildagliptin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Type 2 Diabetes Mellitus, Glycemic variability", 
        "lastchanged_date": "April 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hyderabad", 
                        "country": "India", 
                        "state": "Andhra Pradesh", 
                        "zip": "500 096"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Delhi", 
                        "country": "India", 
                        "state": "Delhi", 
                        "zip": "110076"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "state": "Karnataka", 
                        "zip": "560017"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "state": "Karnataka", 
                        "zip": "560034"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mumbai", 
                        "country": "India", 
                        "state": "Maharashtra"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pune", 
                        "country": "India", 
                        "state": "Maharashtra", 
                        "zip": "411004"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pune", 
                        "country": "India", 
                        "state": "Maharashtra", 
                        "zip": "411 040"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madurai", 
                        "country": "India", 
                        "state": "Tamil Nadu", 
                        "zip": "625 020"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lucknow", 
                        "country": "India", 
                        "state": "Uttar Pradesh", 
                        "zip": "226003"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lucknow", 
                        "country": "India", 
                        "state": "Uttar Pradesh", 
                        "zip": "226014"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Varanasi", 
                        "country": "India", 
                        "state": "Uttar Pradesh", 
                        "zip": "221 005"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kolkatta", 
                        "country": "India", 
                        "state": "West Bengal", 
                        "zip": "700 027"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bhubaneswar", 
                        "country": "India", 
                        "zip": "751005"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coimbatore", 
                        "country": "India", 
                        "zip": "641009"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coimbatore", 
                        "country": "India", 
                        "zip": "641018"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kolkata", 
                        "country": "India", 
                        "zip": "700054"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Delhi", 
                        "country": "India", 
                        "zip": "110017"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Delhi", 
                        "country": "India", 
                        "zip": "110 017"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Comparative Study to Assess the Effect of Vildagliptin Versus Glimepiride on Glucose Variability in Type 2 Diabetic Patients Uncontrolled on Metformin Alone", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Drugs Controller General of India (DCGI)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "MAGE has been shown to be independent of mean glycaemia and the greater the MAGE, the higher the glycaemic fluctuations. MAGE will be calculated from the arithmetic mean of the differences between consecutive peaks and nadirs; measurement in the peak-to-nadir or nadir-to-peak direction is determined by the first qualifying excursion (defined as exceeding the value of one standard deviation of the blood glucose for the same 24-hour period).", 
            "measure": "Mean amplitude of glycemic excursions (MAGE) using continuous glucose monitoring system (CGMS)", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01910441"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percent glycosylated hemoglobin reduction from baseline at 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "description": "Glycemic control is defined as hypoglycemic range/hyperglycemic range and ideal glycemic range\"", 
                "measure": "Time to glycemic control assessed through CGMS", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "description": "Patients reaching the glycemic target of (i) HbA1c \u2264 6.5% and (ii) HbA1c \u2264 7.0%", 
                "measure": "Percentage of patients reaching the glycemic targets after 16 weeks treatment, in the overall study population", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "Number of unrecognized hypoglycemia events recognized by CGMS", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "measure": "Number of patients with adverse events, serious adverse events and death", 
                "safety_issue": "Yes", 
                "time_frame": "16 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}